MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Adenosine antagonists"

  • 2024 International Congress

    Shifting Tides of Caffeine: Evaluating Consumption Patterns In Parkinson’s disease Progression

    S. Bouhadoun, S. Zolfaghari, A. Delva, T. Kouchache, A. Pelletier, R. Postuma (Montréal, Canada)

    Objective: This investigation aims to explore temporal shifts in caffeine consumption throughout the Parkinson’s disease (PD) course. Background: Caffeine has been consistently associated with a…
  • 2024 International Congress

    Health Care Utilization at the End-Of-Life in Parkinson´s Disease

    B. Leavy, E. åkesson, J. Lökk, T. Schultz, P. Strang, E. Franzén (Stockholm, Sweden)

    Objective: This study aims to increase knowledge concerning end of life health care utilization among an urban-dwelling Parkinson's disease (PD) cohort. More specifically we investigated frequency…
  • 2024 International Congress

    Effect of Istradefylline on Motor and Non-motor Symptoms in Patients with Parkinson’s Disease: the ISTRA ADJUST PD Randomized, Controlled Study

    H. Nagayama, T. Hatano, R. Sengoku, N. Yanagisawa, O. Kano (Tokyo, Japan)

    Objective: To examine the effects of istradefylline on motor and non-motor symptoms in Parkinson’s disease (PD) patients with wearing-off phenomena. Background: Previous results [1,2] of…
  • 2024 International Congress

    Istradefylline effects on L-Dopa resistant tremor in Parkinson’s disease

    G. Ozay, I. Zhang, M. Umali, L. Lovelace, M. Barry, L. Ariza Serrano, A. Sharma, L. Raslan, Y. Torres-Yaghi, F. Pagan (Washington, USA)

    Objective: Quantifying Istradefylline(IST) effects in L-Dopa(LD) resistant tremor in Parkinson’s disease(PD) patients. Background: The adenosine A2A receptors control the indirect pathway. Adenosine A2A receptor activation decreases…
  • 2024 International Congress

    Efficacy of Novel A2A/A1 Antagonist in Motor and non-Motor Symptoms of MPTP-Treated Macaques

    J. Jung, Y. Lee, Y. Kim (Hwaseong-si, Gyeonggi-do, Republic of Korea)

    Objective: Our primary objective was to test the novel adenosine A2A/A1 receptor antagonist IDAA-338 in alleviating Parkinsonian symptoms when given as a mono or as…
  • 2023 International Congress

    Istradefylline effect on Parkinson’s Disease Tremor, Motor symptoms and non-Motor symptoms.

    K. Chandrakumar, B. Wilmarth, B. Nagle, G. Di Maria, O. Gonul, L. Lovelace, E. Waldon, K. Getchell, Y. Torres-Yaghi, F. Pagan (Washington, USA)

    Objective: Istradefylline is FDA approved for use in patients with PD treated with carbidopa-levodopa to reduce off time. GUH Movement Disorder Group has observed that…
  • 2023 International Congress

    Impact of istradefylline on the onset of dyskinesia in Parkinson’s Disease patients with wearing off: a randomized controlled study (ODYSSEI)

    Y. Tsuboi, T. Hasegawa, Y. Shimo, S. Kaneko, M. Tomiyama, K. Kashihara, S. Chiu, T. Yamaguchi (Fukuoka, Japan)

    Objective: To determine the effect of long-term treatment with istradefylline (IST) on the time to onset of dyskinesia in Parkinson’s disease (PD) patients with wearing-off…
  • 2023 International Congress

    The development of a multiplex allele specific PCR to improve the diagnostic yield of NGS in the GBA gene screening

    C. Panteghini, C. Reale, I. Colangelo, M. Suerz, R. Cilia, R. Eleopra, B. Garavaglia, F. Invernizzi (Milano, Italy)

    Objective: Our aim is to offer a complete and reliable diagnostic service excluding false negative. Background: Heterozygous variants in the GBA gene are the most…
  • 2022 International Congress

    Effect of KW-6356, a novel adenosine A2A receptor antagonist/inverse agonist, on motor and non-motor symptoms in Parkinson’s disease patients as an adjunct to levodopa therapy: Results of Phase 2b study

    T. Maeda, K. Sugiyama, K. Yamada, M. Nishi, N. Hattori (Iwate, Japan)

    Objective: To evaluate the efficacy and safety of KW-6356 in Parkinson’s disease (PD) patients with levodopa therapy, irrespective of the presence of wearing-off (WO). Background:…
  • 2022 International Congress

    Levodopa-induced unilateral orofacial dystonia in multiple system atrophy : case report and video presentation

    C. Dong, H. Sun, S. Liu, P. Chan (Beijing, China)

    Objective: The study reports a case of lateral orofacial dystonia in a multiple system atrophy (MSA) patient treated with levodopa, and discusses the clinical characteristics…
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley